COMMITTED TO ENGINEERING TRANSFORMATIVE THERAPIES FOR AUTOIMMUNE DISEASES

STRIVING TO REDEFINE OUTCOMES FOR TENS OF THOUSANDS OF PEOPLE

DEVELOPING INNOVATIONS DESIGNED TO GIVE PEOPLE CONTROL OVER THEIR HEALTH

Our Vision

Normal lives for people with autoimmune diseases

Therapeutic Focus

Autoimmune diseases occur when the immune system is unable to distinguish between harmful pathogens and the body’s own healthy tissues. These diseases target both specific organs and broader bodily systems.

Company Overview

Click here to see our current Corporate Presentation

Pipeline

Immunovant’s two investigational product candidates, batoclimab (“IMVT-1401”) and IMVT-1402, are novel, fully human monoclonal antibodies targeting the neonatal Fc receptor (FcRn). We believe that each of these product candidates has the potential to address a variety of IgG-mediated autoimmune diseases as a self-administered subcutaneous injection.

Read More